"Established in 1977, Chicago ENT is Chicagoland’s premier ear, nose, and throat specialty center. Led by world-renowned otolaryngologist, thyroid and parathyroid surgeon, and sleep specialist Dr. Michael Friedman, the center was the first to provide integrated, comprehensive care for sleep apnea, thyroid and parathyroid disease, and all diseases of the ear, nose, and throat. Chicago ENT specialists see patients at four locations in the Chicago area: Lincoln Park, Bucktown, Chicago North and Skokie."

During the past decade, Chicago ENT conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 5 clinical trials were completed, i.e. on average, 71.4% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 4 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chicago ENT" #1 sponsor was "Optinose US Inc." with 2 trials, followed by "Otonomy, Inc." with 2 trials sponsored, "AnaptysBio, Inc." with 1 trials sponsored, "GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc." with 1 trials sponsored and "ImThera Medical, Inc." with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chicago ENT" #1 collaborator was "Pearl Pathways" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Chicago ENT" are "Bilateral Nasal Polyposis" (2 trials), "Chronic Rhinosinusitis" (1 trials), "Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps" (1 trials), "Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)" (1 trials) and "Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)" (1 trials). Many other conditions were trialed in "Chicago ENT" in a lesser frequency.

Most popular intervention types in "Chicago ENT" are "Drug" (7 trials), "Device" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "OTO-313" (2 trials), "Etokimab" (1 trials), "Fluticasone Propionate" (1 trials) and "GB001" (1 trials). Other intervention names were less common.

The vast majority of trials in "Chicago ENT" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Chicago ENT". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Chicago ENT, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Chicago ENT, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".